Maze Therapeutics Inc. (MAZE)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist
Maze Therapeutics, Inc. has advanced two lead precision medicine programs, MZE782 for PKU and MZE829 for APOL1-mediated kidney disease, with significant clinical progress. MZE782 demonstrated a best-in-class pharmacodynamic profile in Phase 1, supporting a transformative potential for PKU management; Phase 2 is set for mid-2026. MZE829 achieved strong uACR reductions in early Phase 2 data for AMKD, but faces competition from Vertex's inaxaplin; pivotal trials are planned for 1H 2027.
Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Maze Therapeutics, Inc. (MAZE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $1.15 per share a year ago.
Maze Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 20 | $557.5 | $517.4 | -$40.1 | -7.19% |
 Farallon Capital Farallon Capital Management LLC | 1.11M | $33.06M | $28.78M | -$4.28M | -12.95% |
| BG Bart Gancher Intech Investment Management LLC | 8,594 | $320,383.02 | $246,218.1 | -$74,164.92 | -23.15% |
| NM Nir Messafi Deep Track Capita LLP | 3.73M | $55.59M | $96.56M | $40.97M | 73.7% |
 Joseph Castro Nuveen LLC | 78,468 | $2.37M | $2.03M | -$335,772 | -14.19% |
Maze Therapeutics Inc. (MAZE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Maze Therapeutics Inc. ever had a stock split?
Maze Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jason Coloma CEO | NASDAQ (NMS) Exchange | 578784100 CUSIP |
| US Country | 141 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Maze Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development of small molecule precision medicines targeted at treating renal, cardiovascular, related metabolic diseases, and obesity in the United States. Established in 2017 and based in South San Francisco, California, Maze Therapeutics was formerly known as Modulus Therapeutics, Inc., a name change that occurred in September 2018. The company is actively advancing its clinical programs, aiming to address significant unmet needs in the healthcare landscape.
Products and Services
- MZE829 – MZE829 is an oral small molecule inhibitor specifically designed to target apolipoprotein L1. Currently, it is in Phase II clinical trials aimed at treating patients suffering from APOL1 kidney disease. This innovative approach seeks to improve renal function and overall patient outcomes.
- MZE782 – MZE782 is another oral small molecule inhibitor, but it focuses on inhibiting the solute transporter SLC6A19. The product is in Phase I clinical trials, and it is intended for use in treating chronic kidney disease. This therapy represents a step forward in addressing the challenges faced by patients with degenerative kidney conditions.
